Tenderwize
Retour à la recherche

Open-house rebate agreement for Anakinra

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Aug 03, 2027 · 339 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Anakinra, ATC L04AC03

62/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

62 / 100

Complexité

58 / 100

Facteurs de risque

The notice explicitly says the contract documents must be submitted through the communication area in the DTVP portal a...

Only pharmaceutical companies are eligible as potential contract partners, and suitability must be proven by a signed d...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Sep 2027
  • Non-exclusive rebate agreements for the active substance Anakinra, ATC L04AC03.
  • Open-house model with identical, non-negotiable contract terms for all eligible pharmaceutical companies.
Afficher le résumé complet

Open-house supply arrangement for pharmaceutical products: non-exclusive rebate agreements for Anakinra (ATC L04AC03) offered by AOK Bayern to all interested pharmaceutical companies meeting the stated suitability requirement. This is explicitly described as an open-house model, not a competitive award procedure, with identical non-negotiable contract terms and no selection among bidders. Contracting is possible during the term, with the earliest start on 2025-10-01 and latest contract conclusion by 2027-08-03. Submission can be paper or electronic via DTVP, but the contract documents must be submitted through the communication area, not the offer area.

Risques

The notice explicitly says the contract documents must be submitted through the communication area in the DTVP portal a...

Only pharmaceutical companies are eligible as potential contract partners, and suitability must be proven by a signed d...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.
  • The contract must be submitted signed; signatory authority must be evidenced by the commercial register extract or a power of attorney must be provided.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open-house rebate agreement for Anakinra

Single lot for non-exclusive pharmaceutical rebate agreements concerning Anakinra, ATC L04AC03. Scope is pharmaceutical supplies under an open-house model; contract terms are pre-set and not individually negotiable. The lot is for Germany, with performance in Bavaria (DE212).

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Sep 2025 - Sep 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Aug 03, 2027

Détails de la procédure

Date de publication
13 Aug 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
532705-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30